PMSO yields 2000000.00% · ABBV yields 3.06%● Live data
📍 PMSO pulled ahead of the other in Year 1
Combined, PMSO + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PMSO + ABBV for your $10,000?
Primal Solutions, Inc. develops and provides managed software solutions to communications service providers. Its solutions enable communications service providers to automatically capture, correlate, track, manage, monetize, and analyze their communications transaction data. The company's services include applications management services; business process outsourcing services; local and remote data center services; professional services, which comprise planning, business process consulting, training, and implementation support; and customer support services. Its solutions support voice, data, or video services. The company's solutions are used in 70 paging, cellular, wire line, fiber, and hybrid fiber-coaxial networks to support subscribers and transactions. It sells its products through direct sales force and channel partners primarily in the United States. The company was formerly known as Primal Systems, Inc. and changed its name to Primal Solutions, Inc. in October, 1999. The company was incorporated in 1996 and is based in Irvine, California. Primal Solutions, Inc. is a former subsidiary of Billing Services Group Limited.
Full PMSO Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.